CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Hematology
Reference40 articles.
1. Long-term outcome of patients in the LNH-98. 5 Trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte;Coiffier;Blood.,2010
2. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol.,2011
3. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study;van Imhoff;J Clin Oncol.,2017
4. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol.,2010
5. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study;Crump;Blood.,2017
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting Tumors;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28
2. Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy;Frontiers in Oncology;2024-08-19
3. Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma;Advances in Therapy;2024-06-25
4. Real-world evaluation of health-related quality of life in patients with diffuse large B-cell lymphoma based on a multinational survey;Frontiers in Oncology;2024-06-24
5. Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy;Frontiers in Molecular Medicine;2024-02-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3